Scientific work

Prof. Dr. Cafer Adıgüzel

142 publications. The source of the information is stated next to each publication.

Back to profile

  1. A1. Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J.An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost. 2022 Jan-Dec;28

    Source: medicana.com.tr profile page

  2. A2. Umit EG, Kara O, Adiguzel C. (Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33-41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43-50.) Curr Med Res Opin. 2020 Apr;36(4):607.

    Source: medicana.com.tr profile page

  3. A3. Yabas Kiziloglu O, Mestanoglu M, Totuk Gedar OM, Adiguzel C, Toygar O. Recurrence of acute lymphoblastic leukemia manifesting as serous retinal detachments and optic disc swelling.Int Ophthalmol. 2018 Aug;38(4):1791-1795.

    Source: medicana.com.tr profile page

  4. A4. Kantarcıoğlu B, Türköz HK, Yılmaz G, Pepedil Tanrıkulu F, Kaygusuz Atagündüz I, Adıgüzel C, Fıratlı Tuğlular T. Aplastic anemia associated with oral terbinafine: a case report and review of the literature. Turk J Haematol. 2014 Dec 5;31(4):411-6.

    Source: medicana.com.tr profile page

  5. A5. Toptas T, Kaygusuz-Atagunduz I, Kani HT, Adiguzel C, Firatli-Tuglular T. Levofloxacin for the treatment of severe refractory BK virus-associated hemorrhagic cystitis in hematopoietic stem cell transplantation recipients: A report of three cases. Oncol Lett. 2014 Oct;8(4):1775-1777.

    Source: medicana.com.tr profile page

  6. A6. Fareed J, Adiguzel C, Thethi I.Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J. 2011 Mar 28;9(1):5.

    Source: medicana.com.tr profile page

  7. A7. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract . 64(7):956-67 (2010).

    Source: medicana.com.tr profile page

  8. A8. Kaygusuz I, Koc M, Arikan H, Adiguzel C, Cakalagaoglu F, Tuglular TF, Akoglu E. Focal segmental glomerulosclerosis associated with idiopathic myelofibrosis. Ren Fail. 32(2):273-6 (2010).

    Source: medicana.com.tr profile page

  9. A9. Knesek MJ, Litinas E, Adiguzel C, Hopkinson W, Hoppensteadt D, Lassen M, Fareed J. Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins. Clin Appl Thromb Hemost. 16(1):42-50 (2010).

    Source: medicana.com.tr profile page

  10. A10. Zhu H, Hoppensteadt D, Iqbal O, Litinas E, Adiguzel C, Fareed J. Relative purity of different bovine thrombin preparations. Clin Appl Thromb Hemost. 15(6):681-8 (2009).

    Source: medicana.com.tr profile page

  11. A11. Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost. 15(6):645-51 (2009).

    Source: medicana.com.tr profile page

  12. A12. Sayitoglu, M., I.C. Haznedaroğlu, O. Hatirnaz, Y. Erbilgin, S. Aksu, E. Koca, C. Adiguzel, M. Bayik, I. Akalin, Z. Gülbas, M. Akay, A. Unal, L. Kaynar, E. Ovali, M. Yilmaz, M. Yenerel, S. Dagdas, G. Ozet, C. Ar, Y. Aydin, T. Soysal, B. Durgun, O. Ozcebe, A. Tukun, O. Ilhan ve U.Ozbek. “Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia” J Int Med Res, 37, 1018-1028 (2009).

    Source: medicana.com.tr profile page

  13. A13. Adiguzel, C., O. Iqbal, D. Hoppensteadt, W. Jeske, J. Cunanan, E. Litinas, H. Zhu, J.M. Walenga ve J. Fareed. “Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide”. Clin Appl Thromb Hemost, 15(5):501-11. (2009).

    Source: medicana.com.tr profile page

  14. A14. Kannan, M., R. Saxena, C. Adiguzel ve J. Fareed. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost , 35, 337-343 (2009).

    Source: medicana.com.tr profile page

  15. A15. Adiguzel, C., V. Bansal, E. Litinas, J. Cunanan, O. Iqbal, K. Nelson, M. Kannan, D. Hoppensteadt ve J. Fareed. “Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin”. Clin Appl Thromb Hemost, 15, 145-151 (2009).

    Source: medicana.com.tr profile page

  16. A16. Adiguzel, C., W.P. Jeske, D. Hoppensteadt, J.M. Walenga, V. Bansal ve Fareed J. “Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products”. Clin Appl Thromb Hemost, 15, 137-144 (2009).

    Source: medicana.com.tr profile page

  17. A17. Adiguzel, C., S.U. Bozkurt, I. Kaygusuz, A. Uzay, Tecimer T, ve M. Bayik. “Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature”. APMIS, 117, 222-229 (2009).

    Source: medicana.com.tr profile page

  18. A18. Heilmann, L., M. Schorch, T. Hahn, G. Adasz, K. Schilberz, C. Adiguzel ve J. Fareed. “Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study”. Semin Thromb Hemos. 34, 794-802 (2008).

    Source: medicana.com.tr profile page

  19. A19. Zhu, H., D. Hoppensteadt, C. Adiguzel, R.L. Bick ve J. Fareed. “Comparison of immunogenic potentials of bovine thrombin preparations”. Clin Appl Thromb Hemost, 15, 41-49 (2009).

    Source: medicana.com.tr profile page

  20. A20. Zhu, H., D. Hoppensteadt, R. Wahi, J. Cunanan, C. Adiguzel, R. Bick ve J. Fareed. “Reduced Immunogenic Potential of Membrane Filtered Bovine Thrombin Preparations for Hemostatic Application”. Clin Appl Thromb Hemost, 15, 32-40 (2009).

    Source: medicana.com.tr profile page

  21. A21. Clark, M., D. Hoppensteadt, J. Walenga, L. Myers, J. Cunanan, W. Jeske, C. Adiguzel, O. Iqbal ve J. Fareed. “Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate”. Int Angiol, 27, 370-376 (2008).

    Source: medicana.com.tr profile page

  22. A22. Iqbal, O., C. Adiguzel, B.E. Lewis, J. Cunanan ve J. Fareed. “Argatroban in percutaneous Coronary interventions”. Semin Thromb Hemost, 34(Suppl 1), 62-74 (2008).

    Source: medicana.com.tr profile page

  23. A23. Adiguzel, C., O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J.M. Walenga ve J. Fareed. “Potency adjusted generic versions of argatroban can be differentiated from branded argatroban in thrombin generation and platelet activation assays”. Semin Thromb Hemost, 34(Suppl 1), 108-117 (2008).

    Source: medicana.com.tr profile page

  24. A24. Fareed, J., J.M. Walenga, W. Jeske, D. Hoppensteadt, M. Prechel, O. Iqbal, C. Adiguzel, M. Clark, E. Litinas, J. Cunanan, R. Linhardt ve J. Harenberg. “Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recall heparin”. Semin Thromb Hemost, 34(Suppl 1), 119-127 (2008).

    Source: medicana.com.tr profile page

  25. A25. Fareed, J., W. Jeske, D. Fareed, M. Clark, R. Wahi, C. Adiguzel ve D. Hoppensteadt. “Are all low molecular weight heparins equivalent in the management of venous thromboembolism?” Clin Appl Thromb Hemost, 14, 385-392 (2008).

    Source: medicana.com.tr profile page

  26. A26. Hoppensteadt, D.A., R. Wahi, C. Adiguzel, O. Iqbal, E. Ramacciotti, R.L. Bick, H.L. Messmore, V. Bansal ve Fareed J. “Contaminant in the recalled unfractionated heparin preparations: where is the problem?” Clin Appl Thromb Hemost, 14, 261-266 (2008).

    Source: medicana.com.tr profile page

  27. A27. Fareed, J., O. Iqbal, J. Cunanan, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Chaining trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?” Int Angiol, 27, 176-192 (2008).

    Source: medicana.com.tr profile page

  28. A28. Fareed, J., D.A. Hoppensteadt, D. Fareed, M. Demir, R. Wahi, M. Clarke, C. Adiguzel ve R. Bick. “Survival of heparins, oral anticoagulants, and aspirin after the year 2010”. Semin Thromb Hemost, 34, 58-73 (2008).

    Source: medicana.com.tr profile page

  29. A29. Jeske, W.P., J.M. Walenga, D.A. Hoppensteadt, C. Vandenberg, A. Brubaker, C. Adiguzel, M. Bakhos ve J. Fareed. “Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic”. Semin Thromb Hemost, 34, 74-85 (2008).

    Source: medicana.com.tr profile page

  30. A30. Hoppensteadt, D.A., N. Fabbrini, R.L. Bick, H.L. Messmore, C. Adiguzel, J. Fareed. “Laboratory evaluation of the antiphospholipid syndrome”. Hematol Oncol Clin North Am, 22, 19-32 (2008).

    Source: medicana.com.tr profile page

  31. A31. Bizargity, P., C. Adıguzel, G. Ozilhan, M. Bayık ve E. Eksioglu-Demiralp. “İmatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia”. Clin Lab Haem: 27:1-2 (2005).

    Source: medicana.com.tr profile page

  32. A32. Cetiner, M., C. Adıgüzel, D. Argon, S. Ratip, E. Ekşioğlu-Demiralp, T. Tecimer ve M. Bayık. “Hairy Cell Leukemia in Father and Son”. Med Oncol, 20, 375-378 (2003).

    Source: medicana.com.tr profile page

  33. A33. Demirçay, Z., A. Cömert ve C. Adıgüzel. “Leg Ulsers and Hydroxyurea: Report of Three Cases with Essential Thrombocythemia”. İnternational Journal of Dermatology, 41, 872-874 (2002).

    Source: medicana.com.tr profile page

  34. B1. Dilvin Guney, Aysin Tulunay, Funda Pepedil, Isik Kaygusuz, Cafer Adiguzel, Tülin Tuglular, Muzaffer Demir, Emel Eksioglu-Demiralp, and Fikriye Uras. Tyro3, Axl Ve Mer (TAM) Receptors On Surfaces of Mononuclear Cells in Patients with B-Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4588.

    Source: medicana.com.tr profile page

  35. B2. Debra Hoppensteadt, Hussein Khan, Indermohan Thethi, Muzaffer Demir, Cafer Adiguzel, Saud Rahman, and Jawed Fareed. Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 2294.

    Source: medicana.com.tr profile page

  36. B3. Jawed Fareed, Cafer Adiguzel, Debra Hoppensteadt, Walter Jeske, Jeanine M. Walenga, Bruce E Lewis, Harry L. Messmore, Jr., and Vinod Bansal. Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 4326.

    Source: medicana.com.tr profile page

  37. B4. Microscopic Examination Of Bone Marrow Aspiration Smears: Diagnostic Agreement Of Hematologists And Hematopathologists On Common Hematological Diagnoses T Toptas, M Sungurtekin, G Gokoglu, M Gun, T Kasikci, G Yilmaz, B Kantarcioglu, I Kaygusuz, C Adiguzel, S Bozkurt, T Firatli-Tuglular, M Bayik. 16th Congress of the European Hematology Association London, 2011 (1755).

    Source: medicana.com.tr profile page

  38. B5. Levofloxacin For Bk Virus-Associated Hemorrhagic Cystitis In The Post-Hematopoietic Stem Cell Transplantation Period T Toptas, I Kaygusuz, T Kani, B Kantarcioglu, G Yilmaz, C Adiguzel, T Firatli-Tuglular, M Bayik. 16th Congress of the European Hematology Association London, 2011 (1495).

    Source: medicana.com.tr profile page

  39. B6. The Effect Of Complete Molecular Response On Progression-Free Survival In Patients With Chronic Myeloid Leukemia Receiving Imatinib Mesylate I Kaygusuz, T Toptas, B Kantarcioglu, G Yilmaz, C Adiguzel, E Eksioglu-Demiralp, T Firatli-Tuglular, M Bayik 16th Congress of the European Hematology Association London, 2011 (0154).

    Source: medicana.com.tr profile page

  40. B7. Jawed Fareed, Debra Hoppensteadt, Josephine Cunanan, Walter Jeske, Cafer Adiguzel, He Zhu, Cinara Echart, and Massimo Iacobelli. Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4180.

    Source: medicana.com.tr profile page

  41. B8. Walenga, J., M. Bakhos, D. Hoppensteadt, C. Adiguzel, J. Cunanan ve W. Jeske. “Immunogenicity Of Low Molecular Weight Heparins And Biosimilars”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-399, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  42. B9. Gray, A., D. Hoppensteadt, L. Myers, O. Iqbal, C. Adiguzel, ve J. Fareed. “Assay Dependent Variations In The USP Potency Standardized Unfractionated Heparins”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-136, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  43. B10. Adiguzel, C., E. Litinas, J. Cunanan, D. Hoppensteadt, J. Walenga ve J. Fareed. “Differential Thrombin Generation Inhibition By Branded And Generic Low Molecular Weight Heparins (LMWHs) As Studied By Using Fluorescence Substrate Based Kinetic Method”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-139, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  44. B11. Adiguzel, C., J. Fareed, J. Walenga, D. Hoppensteadt, W. Jeske, O. Iqbal, J. Cunanan ve E. Litinas. “Generic Versions Of Argatroban Can Be Differentiated From Branded Argatroban In The Thrombin Generation Assays (Tga)”. Journal of Thrombosis and Haemostasis. 7 (Suppl 2), PP-MO-140, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  45. B12. Hoppensteadt, D., J. Fareed, V. Bansal, O. Iqbal, C. Adiguzel ve H. Messmore. “Activation Of Prekallikrein By Contaminated Heparins, Isolated Contaminant And Related Hypersulfated Chondroitin Sulfate Preparations: Pharmacologic Implications”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-MO-143, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  46. B13. Bansal, V., E. Litinas, D. Hoppensteadt, C. Adiguzel ve Jawed Fareed. “Contaminants In Heparin! A Call For Substitute Anticoagulants”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-TH-145, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  47. B14. Bansal, V., J. Cunanan, D. Hoppensteadt, C. Adiguzel, O. Iqbal ve J. Fareed. “Fibrinokinetic Deficit In Chronic Kidney Disease And End Stage Renal Disease Patients Contributes To The Hemostatic Abnormalities”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-WE-261, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009).

    Source: medicana.com.tr profile page

  48. B15. Adiguzel, C., J. Walenga, H. Messmore, , D. Hoppensteadt, R. Wahi, ve J. Fareed, “

    Source: medicana.com.tr profile page

  49. Bioavailability Of Over Sulfated Chondroitin Sulfate. Immunologic Implications”. Journal of Thrombosis and Haemostasis, 7 (Suppl 2), PP-TH-390, 2009, (XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, USA, 11-16 July 2009)

    Source: medicana.com.tr profile page

  50. B16. Litinas, E., C. Adiguzel, W. Jeske, D. Hoppensteadt, H. Messmore, J. Walenga ve J. Fareed. “

    Source: medicana.com.tr profile page